Lung cancer is the most common cause of cancer death in the UK, accounting for 21% of all cancer deaths.
Â
With approximately 65% of people in England with stage 1 lung cancer surviving for 5 years or more after diagnosis, the need for early diagnosis is vital for better patient outcomes.
Â
AstraZeneca UK is delighted to have partnered with Clinithink to deliver innovation to lung cancer pathways. The partnership has deployed AI technology to support healthcare providers to increase early diagnosis of lung cancer. Key data from 75,000 patient records in the study indicated that Clinithink’s AI technology could potentially predict the risk of lung cancer at an earlier stage from information within electronic health records.
Â
The project was funded by AstraZeneca UK.
Â
With approximately 65% of people in England with stage 1 lung cancer surviving for 5 years or more after diagnosis, the need for early diagnosis is vital for better patient outcomes.
Â
AstraZeneca UK is delighted to have partnered with Clinithink to deliver innovation to lung cancer pathways. The partnership has deployed AI technology to support healthcare providers to increase early diagnosis of lung cancer. Key data from 75,000 patient records in the study indicated that Clinithink’s AI technology could potentially predict the risk of lung cancer at an earlier stage from information within electronic health records.
Â
The project was funded by AstraZeneca UK.
